With 800 staff members across 21 countries, Synteract is an international full-service contract research organization with a successful three-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. Synteract has conducted Phase I-IV studies on six continents and in more than 60 countries, offering broad therapeutic expertise, with notable depth in oncology, immunotherapy, CNS, and infectious disease, among other indications. With its “Shared Work – Shared Vision” philosophy, Synteract provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.
Not updated yet!
Synteract has conducted Phase I-IV studies on six continents and in more than 60 countries. We offer broad therapeutic expertise, with notable depth in oncology, immunotherapy, CNS, respiratory, pediatrics, metabolic disorders, and infectious disease, among other indications. We have conducted many companion diagnostic studies and have also worked with drugs addressing rare and orphan diseases.
For many years, we have guided virtual, emerging and mid-sized biopharma companies through the clinical trial and regulatory process by offering both full-service projects and standalone specialties. We know that no two clinical trials are alike; each holds its own unique set of circumstances. Some require full consulting and implementation, from start to finish; others need only additional support on a component or two because you have your own in-house staff or other specialists working with you. This is why we offer our services as part of a full-service project, as a standalone service, or simply consult on any component of a clinical trial where you need some unbiased guidance.